G. Cropp

1.4k total citations
41 papers, 1.1k citations indexed

About

G. Cropp is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, G. Cropp has authored 41 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 24 papers in Molecular Biology and 12 papers in Cancer Research. Recurrent topics in G. Cropp's work include Cancer Treatment and Pharmacology (23 papers), Cancer, Hypoxia, and Metabolism (10 papers) and Multiple Myeloma Research and Treatments (9 papers). G. Cropp is often cited by papers focused on Cancer Treatment and Pharmacology (23 papers), Cancer, Hypoxia, and Metabolism (10 papers) and Multiple Myeloma Research and Treatments (9 papers). G. Cropp collaborates with scholars based in United States, Australia and Estonia. G. Cropp's co-authors include Alison L. Hannah, Alison Stopeck, Robert G. Johnson, Shanu Modi, Jennifer J. Wheler, Weining Ma, Michael S. Gordon, Clifford A. Hudis, David B. Solit and David S. Mendelson and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

G. Cropp

41 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
G. Cropp United States	17	650	518	193	159	158	41	1.1k
Michelle L. Kraus United States	7	466 0.7×	447 0.9×	145 0.8×	52 0.3×	124 0.8×	9	1.1k
Joan MacNeill United States	6	841 1.3×	303 0.6×	111 0.6×	123 0.8×	170 1.1×	6	1.1k
B A Teicher United States	11	588 0.9×	407 0.8×	136 0.7×	66 0.4×	76 0.5×	11	902
Richard Woessner United States	20	1.2k 1.9×	738 1.4×	183 0.9×	176 1.1×	91 0.6×	45	1.6k
Jessica Adickes United States	4	1.4k 2.2×	548 1.1×	200 1.0×	78 0.5×	102 0.6×	4	1.9k
Julia Kirshner United States	15	368 0.6×	379 0.7×	175 0.9×	58 0.4×	75 0.5×	30	848
Heriberto Bruzzoni‐Giovanelli France	15	570 0.9×	281 0.5×	179 0.9×	80 0.5×	64 0.4×	23	932
Tadakazu Akiyama Japan	15	561 0.9×	303 0.6×	116 0.6×	97 0.6×	43 0.3×	17	832
Gennaro Colella Italy	16	800 1.2×	439 0.8×	106 0.5×	70 0.4×	94 0.6×	29	1.1k

Countries citing papers authored by G. Cropp

Since Specialization

Citations

This map shows the geographic impact of G. Cropp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Cropp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Cropp more than expected).

Fields of papers citing papers by G. Cropp

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Cropp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Cropp. The network helps show where G. Cropp may publish in the future.

Co-authorship network of co-authors of G. Cropp

This figure shows the co-authorship network connecting the top 25 collaborators of G. Cropp. A scholar is included among the top collaborators of G. Cropp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Cropp. G. Cropp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lam, Elaine T., Sanjay Goel, Larry J. Schaaf, et al.. (2011). Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 69(2). 523–531. 15 indexed citations

Konner, Jason, Rachel N. Grisham, Jae H. Park, et al.. (2011). Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma. Investigational New Drugs. 30(6). 2294–2302. 9 indexed citations

Monk, J. Paul, Miguel A. Villalona‐Calero, Alison L. Hannah, et al.. (2011). A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors. Investigational New Drugs. 30(4). 1676–1683. 3 indexed citations

Hamlin, Paul A., Carol Aghajanian, David S. Hong, et al.. (2008). First-in-Human Phase 1 Dose Escalation Study of NPI-0052, a Novel Proteasome Inhibitor, in Patients with Lymphoma and Solid Tumor. Blood. 112(11). 4939–4939. 5 indexed citations

Mita, Akira, Kyriakos P. Papadopoulos, Elisabeth I. Heath, et al.. (2008). Phase I study of NPI-2358 (a novel vascular disrupting agent) in patients with solid tumors and lymphomas. Journal of Clinical Oncology. 26(15_suppl). 3525–3525. 6 indexed citations

LoRusso, Patricia, Lorrin Yee, K. Papadopoulos, et al.. (2007). Phase 1 clinical trials of NPI-2358 (a novel vascular disrupting agent) in patients with solid tumors and lymphomas. Molecular Cancer Therapeutics. 6. 1 indexed citations

Richardson, Paul G., Asher Chanan‐Khan, Sagar Lonial, et al.. (2007). Tanespimycin (T) + Bortezomib (BZ) in Multiple Myeloma (MM): Confirmation of the Recommended Dose Using a Novel Formulation.. Blood. 110(11). 1165–1165. 24 indexed citations

Richardson, Paul G., Asher Chanan‐Khan, Sagar Lonial, et al.. (2007). Tanespimycin (T) + bortezomib (BZ) in multiple myeloma (MM): Pharmacology, safety and activity in relapsed/refractory (rel/ref) patients (Pts). Journal of Clinical Oncology. 25(18_suppl). 3532–3532. 8 indexed citations

Modi, Shanu, Alison Stopeck, Michael S. Gordon, et al.. (2007). Combination of Trastuzumab and Tanespimycin (17-AAG, KOS-953) Is Safe and Active in Trastuzumab-Refractory HER-2–Overexpressing Breast Cancer: A Phase I Dose-Escalation Study. Journal of Clinical Oncology. 25(34). 5410–5417. 266 indexed citations

10.

Spear, Matthew A., Patricia LoRusso, A. W. Tolcher, et al.. (2007). A phase 1 dynamic accelerated titration dose escalation study of the vascular disrupting agent NPI-2358. Journal of Clinical Oncology. 25(18_suppl). 14097–14097. 2 indexed citations

11.

Kurzrock, Razelle, Paul A. Hamlin, Anas Younes, et al.. (2007). Phase 1 Clinical Trial of a Novel Proteasome Inhibitor (NPI-0052) in Patients with Lymphomas and Solid Tumors.. Blood. 110(11). 4504–4504. 3 indexed citations

12.

Stopeck, Alison, SL Moulder, Suzanne F. Jones, et al.. (2007). Phase I trial of KOS-1584 (a novel epothilone) using two weekly dosing schedules. Journal of Clinical Oncology. 25(18_suppl). 2571–2571. 20 indexed citations

13.

Villalona‐Calero, Miguel A., Swati Goel, Larry J. Schaaf, et al.. (2006). First-in-human phase I trial of a novel epothilone, KOS-1584. Journal of Clinical Oncology. 24(18_suppl). 2003–2003. 17 indexed citations

14.

Stopeck, Alison, E.D. Thomas, Suzanne F. Jones, et al.. (2006). Phase I trial of a novel epothilone, KOS-1584, using a weekly dosing schedule. Journal of Clinical Oncology. 24(18_suppl). 2041–2041. 10 indexed citations

15.

Chanan‐Khan, Asher, Melissa Alsina, Deborah Doss, et al.. (2005). Dose escalating trial of 17-AAG with bortezomib (BZ) in patients with relapsed refractory multiple myeloma (MM). Journal of Clinical Oncology. 23(16_suppl). 6682–6682. 7 indexed citations

16.

Mitsiades, Constantine S., Asher Chanan‐Khan, Melissa Alsina, et al.. (2005). Phase 1 trial of 17-AAG in patients with relapsed and refractory multiple myeloma (MM). Journal of Clinical Oncology. 23(16_suppl). 3056–3056. 4 indexed citations

17.

Richardson, Paul G., Asher Chanan‐Khan, Melissa Alsina, et al.. (2005). Safety and Activity of KOS-953 in Patients with Relapsed Refractory Multiple Myeloma (MM): Interim Results of a Phase 1 Trial.. Blood. 106(11). 361–361. 27 indexed citations

18.

Adamson, Peter C., Susan M. Blaney, Brenda J. Kitchen, et al.. (2004). Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101. Cancer Chemotherapy and Pharmacology. 53(6). 482–488. 25 indexed citations

19.

Sukbuntherng, Juthamas, G. Cropp, Alison L. Hannah, et al.. (2001). Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416. Journal of Pharmacy and Pharmacology. 53(12). 1629–1636. 41 indexed citations

20.

Eckhardt, S. Gail, Jinee Rizzo, Kevin Sweeney, et al.. (1999). Phase I and Pharmacologic Study of the Tyrosine Kinase Inhibitor SU101 in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 17(4). 1095–1095. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact